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Abstract
Background: Antibodies are essential part of  vertebrates’ adaptive immune system; they can now be produced by transforming 
plants with antibody-coding genes from mammals/humans. Although plants do not naturally make antibodies, the plant-derived 
antibodies (plantibodies) have been shown to function in the same way as mammalian antibodies.
Methods: PubMed and Google search engines were used to download relevant publications on plantibodies in medical and 
veterinary fields; the papers were reviewed and findings qualitatively described.
Results: The process of  bioproduction of  plantibodies offers several advantages over the conventional method of  antibody 
production in mammalian cells with the cost of  antibody production in plants being substantially lesser. Contrary to what is 
possible with animal-derived antibodies, the process of  making plantibodies almost exclusively precludes transfer of  pathogens 
to the end product. Additionally, plants not only produce a relatively high yield of  antibodies in a comparatively faster time, they 
also serve as cost-effective bioreactors to produce antibodies of  diverse specificities.
Conclusion: Plantibodies are safe, cost-effective and offer more advantages over animal-derived antibodies. Methods of  pro-
ducing them are described with a view to inspiring African scientists on the need to embrace and harness this rapidly evolving 
biotechnology in solving human and animal health challenges on the continent where the climate supports growth of  diverse 
plants.
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Introduction
Antibodies, also called immunoglobulins, are a group of  
complex glycoproteins produced by B-lymphocytes and 
present in the serum and tissue fluids of  vertebrates. 
They constitute the humoral arm of  the adaptive im-
mune system, and specifically recognize and bind to tar-
get antigens on pathogens, or toxins produced by such 
pathogens. This individual and specific binding activ-
ity allows antibodies to be used for a variety of  applica-
tions, including the diagnosis, prevention and treatment 
of  disease1-4. When a pathogen enters a vertebrate host, 
antibodies that can bind to antigens on the foreign agent 
are rapidly elicited from B-lymphocytes to combat and 
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eliminate the pathogen. On the antibody, there is a bind-
ing region which varies depending on the conformation 
of  the antigenic determinant (i.e. epitope) on the antigen 
to which it will bind, and a constant region (located on 
the heavy chain) which determines the class and subclass 
of  antibody. For the binding region of  antibody (i.e. the 
paratope) to combine with the corresponding epitope 
on an antigen, there must be suitable atomic groupings 
on opposing parts of  the antigen and antibody, and the 
shape of  the paratope must fit the epitope, so that several 
non-covalent bonds can form simultaneously4.
Defective antibody responses which result in increased 
susceptibility to pyogenic infections could occur due to 
failure of  B-cell function as is seen in X-linked agam-
maglobulinemia, or from failure of  proper T-cell signals 
to B-cells such as occurs in hyper-IgM syndrome, com-
mon variable immunodeficiency and transient hypogam-
maglobulinemia of  infancy4. In overcoming these defects, 
it was discovered that the constant region of  a human 
antibody could be transgenically combined with the bind-
ing region of  an animal host, such as a mouse, to create a 
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recombinant antibody5. This antibody could then be ex-
tracted, purified and administered to combat infections 
in different hosts. Thus, with the advent of  recombinant 
antibody technology, hope of  an affordable treatment for 
diseases such as cancer and diabetes was kindled. How-
ever, although scientists could produce the antibodies, the 
process turned out to be very expensive and dreams of  a 
cheap cure for fatal diseases seemed to disappear6. More 
importantly, purifying the antibodies was problematic as 
different chemicals affected the antibody’s efficacy. Addi-
tionally, mammalian antibodies could have pathogens del-
eterious to humans associated with them7 or they could 
be recognized by the human immune system as foreign 
and trigger a rejection response8. As a result, it was soon 
believed that animal antibodies were not the best option 
for treating diseases. For instance, despite the potential 
of  Hu-E16, a humanized murine monoclonal antibody 
(mAb), and other mAbs as prophylactics and therapeu-
tics for West Nile virus or other infectious diseases, their 
application may be limited by the high production costs 
and scalability associated with mammalian-cell culture 
production system. Moreover, if  biological drugs are too 
costly to produce for resource-poor health care systems, 
their therapeutic potential may never be realized. Thus, 
there is urgent need for development of  production plat-
forms that are cost-effective, scalable, and safe for biolog-
ical therapeutics9. One of  the most promising methods 
of  producing proteins and other biological substances, 
such as antibodies and vaccines, is the use of  transgenic 
plants that contain a gene or genes (known as the trans-
gene) that has been artificially inserted.
Plantibodies: antibodies produced in plants 
Around 1990, plants were first considered as a potential 
host for producing antibodies and the word “plantibody” 
was coined8. The term "plantibodies" describes the prod-
ucts of  plants that have been genetically engineered to 
express antibodies and antibody fragments. With this 
technology, plants are being used as antibody factories 
(bioreactors), utilizing their endomembrane and secre-
tory systems to produce large amounts of  clinically viable 
proteins which can later be purified from the plant tissue. 
Antibodies can be expressed in plants as either full-length 
molecules or as smaller fragments. In essence, a planti-
body is an antibody produced by genetically modified 
plants. Antibodies, originally derived from animals, are 
produced in plants by transforming the latter with animal 
antibody genes. Although plants do not naturally make 
antibodies, plantibodies have been shown to function in 
the same way as normal antibodies10. This concept of  us-
ing plants as heterologous expression system for recom-
binant antibodies (plantibodies) is now more than two 
decades old.
Advantages of  using plants for antibody production
Plantibodies work in a similar fashion to mammalian anti-
bodies; however, compared to conventional methods us-
ing mammalian cells, the use of  plants for antibody pro-
duction offers several unique advantages. Firstly, plants 
are widespread, abundant, and grow quickly; they usually 
mature after one season of  growth and it is possible to 
bring the product to the market within a short time. There-
fore, the cost of  antibodies produced by plants is sub-
stantially less than that from their animal counterparts11. 
Secondly, plants are less likely to introduce adventitious 
human or animal pathogens compared to mammalian 
cells or transgenic animals, thus reducing screening costs 
for viruses, prions and bacterial toxins. Unlike bacterial 
and other prokaryotic systems, plants share a similar en-
domembrane system and secretory pathway with human 
cells9,12. They do not trigger immune responses which 
animal antibodies are prone to doing when exposed to 
foreign/non-self  agents and they also produce a relatively 
high yield of  antibodies in a comparatively shorter time13. 
Additionally, plants are capable of  synthesizing and as-
sembling virtually any kind of  antibody molecule, rang-
ing from the smallest antigen-binding domains and frag-
ments to full-length and even, multimeric antibodies14. 
Plants can be engineered to produce proteins efficiently, 
with significantly lower manufacturing costs than mam-
malian cell cultures15. Moreover, large-scale processing 
infrastructure is already in place for most crops. Hence, 
scale-up is rapid and efficient, requiring only the cultiva-
tion of  additional land13. Also, plants that generate large 
biomass like corn and tobacco can produce large amounts 
of  genetically engineered products while proteins can be 
indefinitely stored on seeds with little reduction in bio-
logical activity11.
Concerns over use of  food crops for antibody pro-
duction
Although plantibodies have been reported to possess 
many advantages, there are concerns that the purity of  
food crop strains could be jeopardized with fears that 
plants carrying antibodies could contaminate food crops 
or that toxin from pesticides or fertilizers could be trans-
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mitted to other plants16. Therefore, it has been suggest-
ed in scientific literature that plants (such as tobacco or 
moss) that do not serve as food for people or feed for 
livestock, should be utilized in the production of  anti-
bodies6. Similarly, the concern over possible toxin trans-
mission to food crops can be greatly reduced and almost 
eliminated by producing plants in contained areas such 
as greenhouses. In this way, plantibodies would not mix 
with other crop strains and the scientists could choose to 
forego spraying the plant hosts with pesticides. Interest-
ingly, being contained in greenhouses would not hamper 
the plants’ production of  plantibodies as large amounts 
of  antibodies can be extracted from relatively small plots 
of  land. For instance, 360 million doses of  plantibodies 
against anthrax can be produced from a single acre of  
tobacco6 while 1.5 kg of  antibodies is provided per acre 
of  corn16. In addition, there are concerns that plants pro-
duce allergenic compounds such as protein glycans and 
other plant antigens17 and those differences in codon us-
age between plants and prokaryotes can lead to inefficient 
expression of  prokaryotic proteins in plants11.
Preference of  tobacco for the production of  planti-
bodies
Several works have shown that soybeans, tobacco, po-
tatoes, corn, alfalfa and similar crops are promising al-
ternative for the production of  recombinant therapeutic 
proteins18,19,20. Leafy crops such as tobacco and alfalfa 
generally have the greatest biomass yields per hectare, be-
cause they can be cropped several times a year13. None-
theless, tobacco has proven to be a favorite preference 
as it offers numerous advantages over other plants as a 
host system6,21. Tobacco grows quickly and through nu-
merous tests, has been shown to produce comparatively 
large amounts of  antibodies. Additionally, tobacco is a 
non-food/non-feed crop, which means that if  grown in 
a greenhouse, the use of  tobacco as a host would elimi-
nate the small chance of  cross-contamination. Being a 
non-food/non-feed crop would also mean that the use 
of  tobacco for antibody production would not remove 
any food staples from the industry or contribute in the 
slightest to a food shortage10.
Methods of  plantibody production
Various techniques have been developed to exploit plants 
as bioreactors for the production of  pharmaceutical an-
tibodies. One of  the several methods for synthesizing 
plantibody is conventional method which uses transfor-
mation and transient expression vector to introduce new 
genes into a host cell. The transformant cell is then in-
troduced into the plant embryo and propagation of  the 
plant in the open field allows large-scale production of  
antibodies10.
Plant tissue culture is the most economic and time-saving 
method for production of  antibodies from plants. To 
achieve this, plant cells in differentiated states are grown 
in bioreactors with foreign proteins harvested from either 
the biomass or culture liquid. Cell cultures contain fewer 
biological proteins or molecules (along with herbicides 
and pesticides) than open field plants or bacterial/yeast 
cell cultures, which may contaminate the product20.
An experiment on tobacco plant established its breeding 
and sexual crossing as a method for production of  plan-
tibody. In this experiment, transformation was used to 
introduce kappa type of  light chain into tobacco plants. 
The same was done with gamma heavy chains. Upon 
crossing one plant with kappa-chains and another plant 
with gamma-chains, an antibody was produced that ex-
pressed both chains14,18.
Some researches suggest use of  transgenic seeds in place 
of  green plant tissue as plants cannot store antibodies for 
an extended period of  time. Seeds contain a low level of  
proteases that allows proteins to be stored without deg-
radation22,23.
Application of  plants as transgenes for biologicals
The use of  transgenic plants for the expression of  mol-
ecules with therapeutic, diagnostic or veterinary appli-
cations has been documented in the last decade. This 
technology represents a great opportunity for the phar-
maceutical industry, since biological products now ac-
count for a large percentage of  all pharmaceutical com-
pounds. Several plant-produced antibodies are presently 
undergoing clinical trials.
i. Therapeutic applications
The first plantibody created from tobacco was called 
CaroRx®. It is a clinically advanced anti-Streptococcus mu-
tans secretory immunoglobulin A plantibody that binds 
specifically to the bacterium, thus protecting humans 
from dental caries that the organism causes23. Another 
plantibody with human medical applications is a human-
ised antibody against herpes simplex virus glycoprotein B 
which was expressed in soybean24.
In a study conducted by Hull et al.25, antibodies engi-
neered to bind to Bacillus anthracis were extracted from 
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transgenic strains of  tobacco and tested in mice. The re-
sult showed that the antibodies were effective in fighting 
the B. anthracis strain and bodes well for the future if  ever 
there is an anthrax epidemic, as there will be a cheap and 
effective prevention of  the disease. 
In a similar study, tobacco-derived plantibodies were ex-
perimentally administered in mice against the Lewis Y 
antigen, which is found on tumour cells in mice and in 
colorectal, breast, lung and ovarian cancer. The results 
showed that the plantibodies had a definitive positive ef-
fect on the cancer-stricken mice by preventing tumour 
formation in them7. Also, treatment or cure for rabies 
through plantibodies has been investigated. A plantibody-
based rabies vaccine produced in tobacco was experimen-
tally administered in hamsters to identify whether it could 
effectively target rabies. According to Ko et al.26, the plan-
tibody proved to be a safe and economically feasible al-
ternative to the current methods of  antibody production 
in animal systems.
Antibodies against ovarian, testicular and colon cancer as 
well as melanoma, B-cell lymphoma and human papillo-
mavirus have already been expressed in transgenic tobac-
co13. These plantibodies are currently being researched 
and are on their way to being approved for human use. 
Plantibodies called DoxoRx and RhinoRx for post-cancer 
therapy and rhinoviruses respectively are in various stages 
of  completion. Already, CaroRx® has been used in human 
trials and a tobacco plantibody against a poultry virus 
(Newcastle disease) has been approved by the USDA27.
ii. Vaccination
The production of  proteins in plants is a major task in 
producing pharmaceutical polypeptides. Potential pro-
teins produced include cytokines, hormones, enzymes, 
epidermal growth factors, interferons, human protein C, 
and pharmaceutical food stuff  which are considered for 
oral immunization. Transgenic plants that express anti-
gens in their edible tissue might be used as an inexpen-
sive oral vaccine production and delivery system. Thus, 
immunization might be possible through consumption 
of  an "edible vaccine"19, to provide active immunization. 
Also, plants produce different classes of  proteins which 
are inexpensive and have increased pharmaceutical value. 
Due to these reasons, transgenic plants are better alterna-
tives. Oral vaccines offer convenient immunization strat-
egies for implementing universal vaccination programs 
throughout the world28. However, compared to vaccines, 
plantibodies have one major demerit - the introduced an-
tibodies are flushed through a person’s system relatively 
quickly, in a matter of  hours or days, before the host’s 
immune system has adapted to producing antibodies. 
Furthermore, vaccines elicit antibody production so that 
one or a few doses can protect the individual for year(s). 
By contrast, if  a plantibody is being used to prevent a 
disease, the patient would need to take doses indefinitely. 
Other disadvantages of  adoption of  antibody expression 
in plants include gene silencing in some instances, differ-
ent patterns of  glycosylation, insufficient expression in 
some plants, allergies or allergic reactions to plant glyco-
proteins and other plant antigens29.
iii. Immunomodulation
Immunomodulation is a molecular technique that allows 
the interference with cellular metabolism or pathogen 
infectivity by the ectopic expression of  genes encoding 
antibodies or antibody fragments30. Applications relying 
on modulating antigen levels in vivo are dependent on ex-
pression and accumulation of  antibodies in specific sub-
cellular compartments and tissues. Passive immunization 
of  plants reduces infection and symptoms caused by vi-
ruses and mollicutes, and significant progress has been 
made towards engineering resistance against insects 30,31. 
Additionally, agro-infiltration of  tobacco has been used 
to produce a diabody against carcinoembryonic antigen32. 
Other than applications in human healthcare, plantibod-
ies may also prove useful as feed additives or for phytore-
mediation19.
iv. Contemporary application: treatment of  Ebola 
patients
The production of  anti-Ebola virus antibodies has re-
cently been explored in plants. Chen et al.33 used a high-
yielding geminivirus-based expression system in the to-
bacco plant, Nicotiana benthamiana, for the production of  
a mAb (6D8) that protected animals from Ebola virus 
infection. Using similar technology and N. benthamiana, 
Bhoo et al.34 produced an Ebola immune complex (EIC) 
by fusing Ebola envelope glycoprotein GP1 to the C-ter-
minus of  the heavy chain (HC) of  humanized 6D8 mAb 
that binds specifically to a linear epitope on GP1. Gemi-
nivirus vector-mediated co-expression of  the GP1-HC 
fusion and the 6D8 light chain in N. benthamiana leaves 
produced assembled immunoglobulin, which was puri-
fied by protein G affinity chromatography. The resultant 
recombinant antibody bound the complement factor 
C1q, indicating immune complex formation. Thereafter, 
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subcutaneous immunization of  mice with purified EIC 
elicited high level production of  anti-Ebola virus anti-
bodies. This was the first published account of  an Ebola 
virus candidate vaccine to be produced in plants.
The ongoing outbreak of  Ebola virus disease in West 
Africa has provided a unique opportunity for the use of  
plantibodies in solving global human health challenges as 
two American medical aid workers who contracted the 
disease in Liberia were successfully treated with an ex-
perimental drug produced in the tobacco plant. The drug, 
called ZMapp, contains a cocktail of  three humanized 
anti-Ebola virus mAbs and was developed by Mapp Bio-
pharmaceutical Incorporated, San Diego35. However, al-
though ZMapp holds great promise for the future, a ma-
jor factor that contributed to its limited use in the ongoing 
West African Ebola outbreak is that producing the huge 
quantity of  anti-Ebola virus antibody cocktail needed on 
a global scale would be challenging as, in its current form, 
ZMapp therapy requires the delivery of  multiple doses of  
highly pure antibody directly into the bloodstream. Con-
sequently, it would be difficult to meet the antibody de-
mand for widespread use in Ebola virus-stricken African 
countries. Moreover, the drug was originally intended for 
expression at levels sufficient for animal trial use36. In ad-
dition, ZMapp is yet to receive approval by the US Food 
and Drug Administration who would have to certify, for 
instance, that the plant extraction process has not led to 
contamination of  the resulting drug37.
Conclusion
Transgenic plants have been shown to be the most pro-
ductive and economical system for making antibodies for 
human use as they play a key role in providing therapeu-
tics and edible vaccines, which are cheap and easy to ad-
minister. This is true considering that not only tobacco, 
but also many other common plants such as corn, moss 
and soybeans have become hosts for antibodies and have 
the capacity to cure, treat or lessen the detrimental effects 
of  multiple diseases. The low-cost, high-scalability, and 
safety characteristics of  a plant-based production system 
offer an attractive alternative for both commercial phar-
maceutical production and for manufacturing products 
for the developing world9. Furthermore, adoption of  
plants as bioreactors on a larger scale would reduce the 
cost of  antibody therapy and increase the number of  pa-
tients with access to these treatments11. In light of  their 
numerous advantages, it seems likely that plantibodies are 
the potential panacea for human and animal health chal-
lenges in the foreseeable future. As their use in solving 
human health problems seem to be increasing, we advo-
cate that their application should also be exploited in the 
field of  veterinary medicine. Lastly, this important bio-
technological breakthrough should be embraced in Af-
rica where there is great diversity of  crops and plants that 
can be readily explored by the pharmaceutical industry 
for therapeutic, immunoprophylactic, improved livestock 
productivity and other purposes.
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